Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

ClinicalTrials.gov ID: NCT01218516

Public ClinicalTrials.gov record NCT01218516. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 8:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in Combination With a Platinum-Containing Doublet in Chemotherapy-Naive Subjects With Stage IV Adenocarcinoma of the Lung (FLAIR)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to compare the effect of farletuzumab versus placebo in combination with either a platinum agent (carboplatin) with paclitaxel or a platinum agent (carboplatin or cisplatin) with pemetrexed followed by farletuzumab or placebo on investigator-assessed progression free survival (PFS) as determined by Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 or definitive clinical disease progression (eg, new occurrence of positive fluid cytology) in chemotherapy naive participants with folate receptoralpha (FRA)-expressing Stage IV adenocarcinoma of the lung.

Study identification

NCT ID
NCT01218516
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Morphotek
Industry
Enrollment
130 participants

Conditions and interventions

Interventions

Biological · Other · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 26, 2011
Primary completion
Dec 14, 2012
Completion
Oct 31, 2013
Last update posted
Aug 19, 2020

2011 – 2013

United States locations

U.S. sites
54
U.S. states
21
U.S. cities
53
Facility City State ZIP Site status
Ironwood Cancer and Research Center Chandler Arizona 85224
Arizona Center for Hematology Oncology Glendale Arizona 85306-4666
Providence Health System Beverly Hills California 90210-5501
Cancer Care Associates of Fresno Medical Group, Inc. Fresno California 93720
Medical Oncology Hematology Gilroy California 95020
California Cancer Care, Inc. Greenbrae California 94904
Moores University of California San Diego Cancer Center La Jolla California 92093
Wilshire Medical Oncology Group La Verne California 91750
Glendale Adventist Medical Center Los Angeles California 90025
Clinical Trials and Research Associates, Inc. Montebello California 90640
North Country Oncology-Hematology Oceanside California 92056
Pacific Hematology Oncology Associates San Francisco California 94115
Central Coast Medical Oncology Santa Maria California 93454
Rocky Mountain Cancer Centers, LLP Denver Colorado 80218-1237
Hematology Oncology Associates, P.C. Stamford Connecticut 06902-3628
Center for Hematology-Oncology Boca Raton Florida 33486
Medical Specialists of the Palm Beaches Deerfield Beach Florida 33441
Broward General Medical Center Fort Lauderdale Florida 33316
Cancer Care of North Florida Lake City Florida 32024
Florida Cancer Institute-New Hope New Port Richey Florida 34655
Ocala Oncology Center, PL Ocala Florida 34474
MD Anderson Cancer Center-Orlando Orlando Florida 32806
University Hematology Oncology, Inc. Centralia Illinois 62801
University of Chicago Medical Center Chicago Illinois 60637
Deaconess Clinic Downtown Evansville Indiana 47713
The Community Hospital Munster Indiana 46321
Kentucky Cancer Center Hazard Kentucky 41701
Baptist Health System, Inc. Lexington Kentucky 40503
Christus Saint Frances, Cabrini Hospital, Cabrini Cancer Center Alexandria Louisiana 71301
Hematology and Oncology Specialists, LLC Metairie Louisiana 70006
National Cancer Institute Bethesda Maryland 20892
Maryland Oncology Hematology, P.A. Columbia Maryland 21044
Berkshire Hematology Oncology, PC Pittsfield Massachusetts 01201
Detroit Clinical Research Center Farmington Hills Michigan 48336
Englewood Hospital and Medical Center Englewood New Jersey 07631
Queens Hospital Center Jamaica New York 11432
Syracuse Veterns Affairs Medical Center Syracuse New York 13210
Willamette Valley Cancer Institute and Research Center Eugene Oregon 97401
St. Luke's Cancer Center Associates Bethlehem Pennsylvania 18015
Gettysburg Cancer Center Gettysburg Pennsylvania 17325
Tennessee Oncology, PLLC Nashville Tennessee 37203
Texas Oncology - Bedford Bedford Texas 76022
University of Texas Medical Branch Galveston Texas 77555
Houston Cancer Institute Houston Texas 77055
Texas Oncology - Plano East Plano Texas 75075-7787
Northwest Cancer Center Sugar Land Texas 77479
Texas Oncology - Tyler Tyler Texas 75702-8363
Texas Oncology - Waco Waco Texas 76712
Virginia Cancer Specialists, PC Fairfax Virginia 22031
Delta Hematology Oncology Associates, PC Portsmouth Virginia 23704
Virginia Mason Medical Center Seattle Washington 98101
Rockwood Cancer Treatment Center Spokane Washington 99204
Medical Oncology Associates, PS Spokane Washington 99208
Cancer Team Bellin Health Green Bay Wisconsin 54313

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.

Recently updated Adenocarcinoma of the Lung trials

Other public records listing Adenocarcinoma of the Lung. Sorted by last update posted; newest first. Not a recommendation.

All Adenocarcinoma of the Lung trials →

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01218516, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 19, 2020 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01218516 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →